Welcome to our dedicated page for Cullinan Oncology news (Ticker: CGEM), a resource for investors and traders seeking the latest updates and insights on Cullinan Oncology stock.
Cullinan Therapeutics, Inc. develops clinical-stage therapies for autoimmune diseases and cancer, with a pipeline centered on T cell engagers and targeted oncology programs. Recurring news includes updates on CLN-978, a CD19xCD3 T cell engager for autoimmune diseases; velinotamig, a BCMAxCD3 program; CLN-049, a FLT3xCD3 bispecific T cell engager for relapsed or refractory AML and MDS; and zipalertinib for EGFR exon 20 insertion-mutated non-small cell lung cancer.
Company announcements commonly cover clinical data presentations, regulatory submissions and FDA communications, portfolio prioritization, collaborations involving zipalertinib, quarterly financial results, cash runway commentary and healthcare investor conference participation.
Cullinan Therapeutics announced preliminary data from its Phase 1 trial of CLN-619, an anti-MICA/B antibody, in combination with pembrolizumab, and updated monotherapy results. Among 22 patients treated with the combination, 3 showed partial responses, including in non-small cell lung cancer (NSCLC) and gastric cancer. Monotherapy results showed a 41.4% clinical benefit rate across various tumor types. CLN-619 was well tolerated, with most adverse events being mild. Cullinan is expanding the trial to include more NSCLC patients and has plans for further studies in multiple myeloma.
Cullinan Therapeutics (Nasdaq: CGEM) reported its Q1 2024 financial results and provided corporate updates. Key highlights include a strong cash position with $434.8 million in cash and investments as of March 31, 2024, and an additional $280 million from an April private placement, extending its cash runway into 2028. The company appointed David Meek to its Board of Directors. Research and development (R&D) expenses decreased to $30.6 million, while general and administrative (G&A) expenses increased to $12.3 million for the quarter. Cullinan reported a net loss of $37.3 million for Q1 2024, down from $58.1 million in Q1 2023. Significant clinical developments include presenting data for CLN-619 at the ASCO 2024 Annual Meeting and focusing CLN-978 on autoimmune diseases, beginning with systemic lupus erythematosus (SLE). The company aims to complete enrollment for the Phase 2b REZILIENT1 study by year-end 2024 and has multiple data catalysts expected through early 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.